Clinical-stage psychedelics company atai Life Sciences (NASDAQ: ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023.
Cash, cash equivalents and short-term investments totaled $209.0 million as of Sept. 30, compared to last quarter’s $227.5 million held (ended June 30, 2023) and the $273.1 million held by Dec. 31, 2022.
See full Q2 results.
Three and nine months R&D expenses of $13.3 million and $48.0 million, vs. $19.0 million and $52.5 million in the same respective periods in 2022.
Three and nine months G&A expenses of $13.6 million and $44.2 million, vs. $19.4 million and $54.7 million in the same respective periods in 2022.
Three-month net income loss attributable to shareholders of $44.2 million, vs. $33.9 million in the same period in 2022.
Long-term debt of $14.96 million by Sept. 30, vs. $14.7 million by Dec. 31, 2022.
The nine-month cash decrease of $64.1 million was mainly due to the $62.2 million net used in operating activities, plus a …